Reported results
- Collaboration revenue was $3.9 million for the quarter ended September 30, 2026.
- Research and development expenses were $32.1 million for the quarter ended September 30, 2026.
- General and administrative expenses were $6.5 million for the quarter ended September 30, 2026.
- Net loss was $29.9 million for the quarter ended September 30, 2026.
- Cash, cash equivalents, and marketable securities were $492.9 million as of September 30, 2026.
Guidance
- Expect preliminary data for AKY-1189 in the first quarter of 2027.
- Expect preliminary data for AKY-2519 in 2027.
- Expect to expand drug supply to include in-house GMP facility in the first half of 2027.
- Cash, cash equivalents, and marketable securities as of September 30, 2026, are expected to fund the Company’s operating plan into 2029.
Price and volatility reaction
The stock moved -4.5% on the print. No front-expiry chain was on file, so there is no straddle expected move.
| Measure | Value | Basis |
|---|---|---|
| Close before release | 17.04 | 2026-11-11 |
| Close after release | 16.28 | 2026-11-12 |
| Realised move | -4.5% | close to close |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
